.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,846,091

« Back to Dashboard

Claims for Patent: 8,846,091

Title:Matrix for sustained, invariant and independent release of active compounds
Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
Inventor(s): Brogmann; Bianca (Ulm, DE), Muhlah; Silke (Biberach, DE), Spitzley; Christof (Elbtal, DE)
Assignee: Euro-Celtique S.A. (Luxembourg, LU)
Application Number:14/058,108
Patent Claims: 1. An oral pharmaceutical formulation comprising: oxycodone or a pharmaceutically acceptable salt thereof present in an amount ranging from 10 to 150 mg; naloxone or a pharmaceutically acceptable salt thereof; and a diffusion matrix containing the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof and comprising: ethylcellulose present in 1-15% by weight of the total formulation; and at least one fatty alcohol present in 10-25% by weight of the total formulation; wherein the matrix is configured to provide sustained, invariant, and independent release of the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof; wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio of 2:1.

2. The pharmaceutical formulation of claim 1, wherein the oxycodone is present as oxycodone hydrochloride.

3. The pharmaceutical formulation of claim 2, wherein the naloxone is present as naloxone hydrochloride.

4. The pharmaceutical formulation of claim 1, wherein the naloxone is present as naloxone hydrochloride.

5. The pharmaceutical formulation of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 10 to 80 mg.

6. The pharmaceutical formulation of claim 5, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 10 to 40 mg.

7. The pharmaceutical formulation of claim 6, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 10 to 30 mg.

8. The pharmaceutical formulation of claim 1, wherein the ethylcellulose is present in 3-12% by weight of the total formulation.

9. The pharmaceutical formulation of claim 8, wherein the ethylcellulose is present in 5-9% by weight of the total formulation.

10. The pharmaceutical formulation of claim 1, wherein the fatty alcohol is present in 15-20% by weight of the total formulation.

11. The pharmaceutical formulation of claim 1, wherein the fatty alcohol is selected from lauryl alcohol, myristyl alcohol, stearyl alcohol, cetylstearyl alcohol, ceryl alcohol, and cetyl alcohol.

12. The pharmaceutical formulation of claim 11, wherein the fatty alcohol is stearyl alcohol.

13. The pharmaceutical formulation of claim 5, wherein the fatty alcohol is stearyl alcohol.

14. The pharmaceutical formulation of claim 6, wherein the fatty alcohol is stearyl alcohol.

15. The pharmaceutical formulation of claim 1, wherein the matrix is further configured to provide equal percentage release per time unit of the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof.

16. The pharmaceutical formulation of claim 15, wherein the equal percentage release per time unit of the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof includes no more than 20% deviation from the mean release value for the oxycodone or pharmaceutically acceptable salt thereof or the naloxone or pharmaceutically acceptable salt thereof.

17. The pharmaceutical formulation of claim 1, wherein the matrix is not based on a polymethacrylate.

18. The pharmaceutical formulation of claim 1, wherein the matrix does not comprise a relevant amount of a hydroxyalkylcellulose.

19. The pharmaceutical formulation of claim 1, wherein the sustained, invariant, and independent release characteristics of the matrix are determined by the ethyl cellulose and the at least one fatty alcohol.

20. The pharmaceutical formulation of claim 1, wherein the formulation is in the form of a tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc